At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 24 enrolled
Drug / intervention
Febuxostatdrug
Likely dose
Febuxostat 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Pharmacological Reversal of Hyperuricemia on Features of the Metabolic Syndrome
University of Texas Southwestern Medical Center·interventional·Posted Jul 31, 2012·Updated Mar 14, 2023
In Brief
A Phase 4 clinical trial evaluating Febuxostat for Gout. Completed, enrolled 24 participants across 1 site.
Detailed Summary
This study is being done to evaluate whether the medication, febuxostat, can improve the degree of insulin resistance and other features of the metabolic syndrome (high blood pressure, elevated insulin levels, excess body fat around the waist, and/or high cholesterol) by lowering uric acid levels in the blood.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGout
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2012
First PostedJul 2012
Primary CompletionMar 2015
TodayJul 2026
First PostedJul 31, 2012
Enrollment StartMay 1, 2012
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 13.9 years ago
Interventions
Febuxostatdrug
One 40 mg tablet once a day for 6 months